Investigational drug · Phase 2
MAX-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Impacted Third Molar Tooth, Tooth Extraction Status Nos.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "MAX-001"
First trial start
2026
Nov 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MAX-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Impacted Third Molar Tooth
- Tooth Extraction Status Nos
Largest trials
Live from ClinicalTrials.gov: studies naming "MAX-001" as an intervention, largest first.
- A Study to Evaluate the Safety and Pain Relief of MAX-001 After Surgical Removal of Wisdom TeethPivotal-lookingNot yet recruiting
Maxona Pharmaceuticals, Inc.Industry
NCT07937657 · 276 participants (planned) · Start Nov 2026 · Primary completion Jun 2027
Drug: MAX-001; Placebo · For: Impacted Third Molar Tooth; Tooth Extraction Status Nos
Sites: Salt Lake City, Utah
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.